ATRN-119: A New Promising ATR Inhibitor for ATM Mutations (And Other HRR Mutations)
/0 Comments/in Not PCa related/by MaxZebrafish Embryo miRNAs: A Potential New Approach to Slow or Stop Cancer Spread
/0 Comments/in Not PCa related, Preclinical Research/by MaxCRISPR is Here to Stay: Gene Therapy Succesfully Used On An Infant With Incurable Disease
/0 Comments/in Not PCa related/by MaxPrecision in Action: How Logic-Gating Redefines Targeted Therapy
/0 Comments/in Not PCa related/by MaxOrally Delivered CRISPR Therapy, Groundbreaking Evolution
/0 Comments/in CRISPR, Not PCa related, Preclinical Research/by MaxA New Compound Looks Promising for Bone Metastasis
/0 Comments/in Not PCa related, Preclinical Research/by MaxHydrogel Breakthrough May Improve Cancer Vaccines
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxModified Virus Shows Promise in Shrinking Tumors and Halting Cancer Growth
/0 Comments/in Not PCa related/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Newsletter 30/2025 July 27, 2025
- New Immunotherapy Strategy Aims to Turn All Solid Tumors Into Immune Targets July 26, 2025
- Scientists Trace Deadly Shift in Prostate Cancer to Two Key Genes July 26, 2025
- Low-Dose Abiraterone Acetate: Phase 1 Trial Looks Very Promising July 25, 2025